Personalized Post-Operative Pain Management

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

September 25, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Persistent Post Operative Opioid UsePost-surgical Pain
Interventions
OTHER

PGx guided personalized post-operative pain management

Patients in the intervention group will receive post operative opioid therapy based on their pharmacogenomic results. Patients who are poor CYP2D6 metabolizers or rapid CYP2D6 metabolizers with moderate or severe pain, will be prescribed either oral hydromorphone 2mg every 4 hours as needed or oral hydromorphone 4mg every 4 hours as needed, respectively. Patients who are intermediate or normal CYP2D6 metabolizers with moderate or severe pain will receive oxycodone 5mg or oxycodone 10mg every 4 hours as needed respectively similar to the treatment offered to the control subjects. Normal or intermediate CYP2D6 metabolizers who are concomitantly taking a drug which is a strong CYP2D6 inducer will be treated as if they are in the rapid metabolizer group, and normal or intermediate patients that are concomitantly taking a drug which is a strong CYP2D6 inhibitor will be treated as if they were a poor metabolizer.

DRUG

Oxycodone

oxycodone

DRUG

Hydromorphone

hydromorphone

Trial Locations (1)

37920

The University of Tennessee Graduate School of Medicine, Knoxville

All Listed Sponsors
lead

University of Tennessee Graduate School of Medicine

OTHER

NCT06669650 - Personalized Post-Operative Pain Management | Biotech Hunter | Biotech Hunter